Predictiv is developing a DNA-based digital twin platform to understand over 22,000 diseases and side effects of around 750 drugs on humans and enable personalized health. This involves sequencing DNA samples to identify genetic diseases that can be prevented and to predict drug reactions. The company claims its platform analyzes all 20,000 genes in a human.
Key customers and partnerships
The company has several partners in the US and Asia for its platform. In February 2021, the company partnered with telehealth provider Kayan Health to offer Predictiv’s platform to healthcare providers who provide patients with a personalized approach to predictive medicine.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.